These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20425063)

  • 41. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?
    Singaram V; Pratley R
    Diab Vasc Dis Res; 2007 Sep; 4(3):237-40. PubMed ID: 17907116
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
    Basile JN
    J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.
    Scheen AJ
    Diabetes Metab; 2018 Nov; 44(5):386-392. PubMed ID: 30126735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?
    Lovre D; Htun W; Carrion C; Fonseca VA
    Curr Diab Rep; 2016 Oct; 16(10):94. PubMed ID: 27541296
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiovascular effects of noninsulin, glucose-lowering agents: need for more outcomes data.
    Joshi PH; Kalyani RR; Blumenthal RS; Donner TW
    Am J Cardiol; 2012 Nov; 110(9 Suppl):32B-42B. PubMed ID: 23062565
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA® trial].
    Gallwitz B; Thiemann S; Wörle HJ; Marx N
    Dtsch Med Wochenschr; 2015 May; 140(11):831-4. PubMed ID: 26080724
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus.
    Li T; Providencia R; Mu N; Yin Y; Chen M; Wang Y; Liu M; Yu L; Gu C; Ma H
    Cardiovasc Diabetol; 2021 Jan; 20(1):30. PubMed ID: 33516224
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of cardiovascular event and mortality in relation to refill and guideline adherence to lipid-lowering medications among patients with type 2 diabetes mellitus in Sweden.
    Karlsson SA; Eliasson B; Franzén S; Miftaraj M; Svensson AM; Andersson Sundell K
    BMJ Open Diabetes Res Care; 2019; 7(1):e000639. PubMed ID: 31114701
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
    Ovalle F
    Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Have we really demonstrated the cardiovascular safety of anti-hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes.
    Packer M
    Diabetes Obes Metab; 2018 May; 20(5):1089-1095. PubMed ID: 29316137
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of current and novel anti-diabetic therapies on cardiovascular risk.
    Ussher JR; Sutendra G; Jaswal JS
    Future Cardiol; 2012 Nov; 8(6):895-912. PubMed ID: 23176691
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials.
    Varin EM; McLean BA; Lovshin JA
    Can J Diabetes; 2020 Feb; 44(1):68-77. PubMed ID: 31699625
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular Protection with Anti-hyperglycemic Agents.
    Deedwania P; Acharya T
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):249-257. PubMed ID: 30767126
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antidiabetes medication initiation trends in US adults with cirrhosis and type 2 diabetes: A nationwide study.
    Simon TG; Wexler DJ; Schneeweiss S; Patorno E
    Diabetes Obes Metab; 2023 Jul; 25(7):2028-2033. PubMed ID: 36938914
    [No Abstract]   [Full Text] [Related]  

  • 59. Complications of diabetes therapy.
    Corathers SD; Peavie S; Salehi M
    Endocrinol Metab Clin North Am; 2013 Dec; 42(4):947-70. PubMed ID: 24286957
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does choice of antidiabetes therapy influence macrovascular outcomes?
    Zarich SW
    Curr Diab Rep; 2010 Feb; 10(1):24-31. PubMed ID: 20425063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.